FDA committee recommends Amgen's denosumab, for the treatment ... will be the first molecule with a novel mechanism of action to enter the osteoporosis market since 2002. Osteoporosis is ...

In a pivotal Phase III trial in post-menopausal osteoporosis patients Amgen announced that denosumab has met its primary and secondary end points of reducing new vertebral fractures, as well as ...

First, nine drugs are currently available in Canada, European or the United States for use with osteoporosis ... that were not previously included (denosumab, raloxifene, strontium, and teriparatide).

Patients who discontinue treatment with the osteoporosis drug denosumab, despite transitioning to zoledronate, show significant losses in lumbar spine bone mineral density (BMD) within a year ...

Amgen's osteoporosis drug, Prolia (denosumab), could have a new use after it showed positive results in glucocorticoid-induced disease. Prolia is already well established, with sales of more than ...

A new study reveals that long-term intake of denosumab in postmenopausal women suffering from osteoporosis was linked with increased bone density. Treatment With Denosumab Better Than Zoledronic ...

Subsequent denosumab doses were associated with lower risks for hypocalcemia among patients with osteoporosis and chronic kidney disease . Magnitude of serum calcium decrease is smaller with ...

FDA’s boxed warning on denosumab follows study results showing increased and early risks of severe hypocalcemia in patients on dialysis. The Food and Drug Administration (FDA) has added a new ...